Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02008656 · ClinicalTrials.gov registry record · Phase 2
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
A Phase 2 study of Rectal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 358
- Enrollment target
- 20
- Study locations
NCT02008656 is a Phase 2 study of Rectal Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 358 participants, below the 3,162-participant average among 70 other Rectal Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02008656, a Phase 2 study of Rectal Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 358 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have an improved 3-year disease-free survival (DFS) compared to patients with similar tumors treated with Chemoradiation therapy (CRT), Total mesorectal excision (TME) and Adjuvant chemotherapy (ACT).
Conditions Studied
Interventions
- DRUG Leucovorin
- DRUG 5-Fluorouracil (5-FU)
- DRUG Oxaliplatin (OXAL)
- DRUG Capecitabine (Xeloda®)
- RADIATION intensity modulated radiotherapy (IMRT)
Study Locations (20)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester Medical Center - Rochester
- Memorial Sloan Kettering Cancer Center at Phelps - Sleepy Hollow
California
- University of California, Irvine - Irvine
- St. Joseph Hospital - Orange
- University of California San Francisco - San Francisco
- John Muir Health - Walnut Creek
Florida
- University Of South Florida - Tampa
- Cleveland Clinic Florida - Weston
Nebraska
- CHI Heath Bergan Mercy - Omaha
- Colon and Rectal Surgery, Incorporated - Omaha
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Bergen - Montvale
Colorado
- University of Colorado - Aurora
District of Columbia
- Washington Hospital Center - Washington D.C.
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2013-11 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02008656
The ClinicalTrials.gov registry entry for NCT02008656 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,162-participant average among 70 other Rectal Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Leucovorin is the first listed.
NCT02008656 reports 20 study locations spanning 10 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02008656 about?
NCT02008656 is a clinical study titled "Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management". The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have an improved 3-year disease-free survival (DFS) compared to patients with...
What is the current status of trial NCT02008656?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 358 participants. The study started on 2013-11. Estimated completion is 2026-11.
What conditions does trial NCT02008656 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT02008656?
The interventions under investigation include: Leucovorin (DRUG), 5-Fluorouracil (5-FU) (DRUG), Oxaliplatin (OXAL) (DRUG), Capecitabine (Xeloda®) (DRUG), intensity modulated radiotherapy (IMRT) (RADIATION).
Who is sponsoring clinical trial NCT02008656?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02008656 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
RECRUITING · Phase 2
-
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.